Chang-hyun K. Oh

Seongbuk, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 75 publications

Discovery of potential RAF selective back pocket as a promising biological site for BRAF inhibitors targeting resistant melanoma opens the door for a new generation of kinase inhibitors: Design, synthesis, biological evaluation, and in silico molecular simulation.

Discovery of potential RAF selective back pocket as a promising biological site for BRAF inhibitors targeting resistant melanoma opens the door for a new generation of kinase inhibitors: Design, synthesis, biological evaluation, and in silico molecular simulation.

Journal: International journal of biological macromolecules

Published: April 24, 2025

Evaluation of novel pyrazol-4-yl pyridine derivatives possessing arylsulfonamide tethers as c-Jun N-terminal kinase (JNK) inhibitors in leukemia cells.

Evaluation of novel pyrazol-4-yl pyridine derivatives possessing arylsulfonamide tethers as c-Jun N-terminal kinase (JNK) inhibitors in leukemia cells.

Journal: European journal of medicinal chemistry

Published: May 18, 2023

Design and synthesis of new adamantyl derivatives as promising antiproliferative agents.

Design and synthesis of new adamantyl derivatives as promising antiproliferative agents.

Journal: European journal of medicinal chemistry

Published: November 03, 2022

Imidazothiazole Derivatives Exhibited Potent Effects against Brain-Eating Amoebae.

Imidazothiazole Derivatives Exhibited Potent Effects against Brain-Eating Amoebae.

Journal: Antibiotics (Basel, Switzerland)

Published: August 29, 2022

A New Combination of Radio-Frequency Coil Configurations Using High-Permittivity Materials and Inductively Coupled Structures for Ultrahigh-Field Magnetic Resonance Imaging.

A New Combination of Radio-Frequency Coil Configurations Using High-Permittivity Materials and Inductively Coupled Structures for Ultrahigh-Field Magnetic Resonance Imaging.

Journal: Sensors (Basel, Switzerland)

Published: August 28, 2022

Antiamoebic Activity of Imidazothiazole Derivatives against Opportunistic Pathogen Acanthamoeba castellanii.

Antiamoebic Activity of Imidazothiazole Derivatives against Opportunistic Pathogen Acanthamoeba castellanii.

Journal: Antibiotics (Basel, Switzerland)

Published: July 28, 2022

Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance via Inhibition of RAF Dimerization in PLX4032-resistant Melanoma.

Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance via Inhibition of RAF Dimerization in PLX4032-resistant Melanoma.

Journal: Anticancer research

Published: February 14, 2022

Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAFV600E/p38α kinase inhibitory activity: Synthesis, in vitro assays and in silico study.

Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAFV600E/p38α kinase inhibitory activity: Synthesis, in vitro assays and in silico study.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: September 29, 2021

Evaluation of the Inhibitory Effects of Pyridylpyrazole Derivatives on LPS-Induced PGE2 Productions and Nitric Oxide in Murine RAW 264.7 Macrophages.

Evaluation of the Inhibitory Effects of Pyridylpyrazole Derivatives on LPS-Induced PGE2 Productions and Nitric Oxide in Murine RAW 264.7 Macrophages.

Journal: Molecules (Basel, Switzerland)

Published: September 07, 2021

Anticancer profile and anti-inflammatory effect of new N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives.

Anticancer profile and anti-inflammatory effect of new N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives.

Journal: Bioorganic chemistry

Published: August 07, 2021

Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.

Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.

Journal: European journal of medicinal chemistry

Published: May 28, 2021

Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E/p38α inhibitors.

Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E/p38α inhibitors.

Journal: European journal of medicinal chemistry

Published: October 29, 2020

Showing 1-12 of 75

Last Updated: 09/26/2026